Quest Laboratories Ltd

Quest Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 16 Mar 2026, hitting its lower circuit limit with a maximum daily loss of 5.0%. The stock closed at ₹106.4, down ₹5.6 from the previous close, reflecting intense selling pressure and panic among investors despite the broader market’s positive momentum.

Quest Laboratories Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 12 March 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Quest Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit price limit on 13 Mar 2026, reflecting robust buying interest and a maximum daily gain of 5.0%. This price action underscores heightened investor enthusiasm despite a backdrop of subdued sector and benchmark indices.

Quest Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 4 Mar 2026, hitting its lower circuit limit with a maximum daily loss of 4.97%. The stock closed at ₹109.05, down ₹5.7 from the previous close, reflecting intense selling pressure and panic among investors.

Quest Laboratories Ltd is rated Strong Buy by MarketsMOJO. This rating was last updated on 16 Feb 2026, reflecting a positive reassessment of the stock’s potential. However, all fundamentals, returns, and financial metrics discussed below are current as of 02 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Quest Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 27 Feb 2026, hitting its lower circuit price limit as panic selling gripped the stock. The share price plunged by 4.99%, underperforming both its sector and the broader Sensex, reflecting intense selling pressure and unfilled supply in the market.

Quest Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 26 Feb 2026, hitting its lower circuit limit amid intense selling pressure. The stock closed at ₹126.25, down 4.97% on the day, underperforming both its sector and the broader market as panic selling gripped investors.

Quest Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 19 Feb 2026, hitting its lower circuit limit amid intense selling pressure. The stock closed at ₹124.55, down 5.0% on the day, reflecting panic selling and unfilled supply that overwhelmed demand despite the company’s strong fundamentals and recent upgrade to a Strong Buy rating.

Quest Laboratories Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 February 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Quest Laboratories Ltd surged to its upper circuit limit on 17 Feb 2026, propelled by strong buying interest and heightened investor participation. The stock closed at ₹128.70, marking a maximum daily gain of 4.98%, significantly outperforming its sector and the broader market indices.

Quest Laboratories Ltd has recently seen its quality grade upgraded from average to good, reflecting significant improvements in its core business fundamentals. This upgrade, accompanied by a strong Mojo Score of 81.0 and a revised Mojo Grade of Strong Buy, signals enhanced operational efficiency, robust profitability, and prudent financial management within the pharmaceuticals and biotechnology sector.

Quest Laboratories Ltd witnessed a remarkable surge on 11 Feb 2026, hitting its upper circuit limit of 20% and closing at ₹129.60. This extraordinary price movement was driven by strong buying interest, significant unfilled demand, and a regulatory freeze on further trading, marking a notable day for the micro-cap pharmaceutical player.

Quest Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 08 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Quest Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 January 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Quest Laboratories Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 01 January 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 05 January 2026, providing investors with the latest view on the company’s position in the market.

Quest Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the most up-to-date perspective on the company’s performance and outlook.